Want to see AU:VIT full AI Analyst Report?
Top Page
Cronos Australia Ltd.
(Sydney:VIT)
Select Model
Select Model
Rating:58Neutral
Price Target:
AU$0.03
▲(3.33% Upside)
Action:Reiterated
Date:07/01/26
The score is driven primarily by moderate financial performance (solid balance sheet but weak cash flow metrics and slightly negative revenue growth) and a clearly bearish technical trend (price below all key moving averages). Valuation is somewhat supportive due to a high dividend yield and a mid-range P/E, but it is not enough to offset the weak trend and cash flow concerns.
Positive Factors
Conservative capital structure
The company’s low debt-to-equity (0.25) and high equity ratio (63.85%) create a conservative capital structure. This reduces refinancing and solvency risk, supports resilience through regulatory or market cycles, and preserves capacity to fund strategic investments or compliance without excess leverage.
Negative Factors
Severe free cash flow decline
A free cash flow collapse of -2056% greatly reduces internal funding for operations, capex and shareholder returns. It forces reliance on external financing, increases liquidity and refinancing risk, and can materially constrain the company’s ability to execute long-term strategic plans or pursue growth opportunities.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative capital structure
The company’s low debt-to-equity (0.25) and high equity ratio (63.85%) create a conservative capital structure. This reduces refinancing and solvency risk, supports resilience through regulatory or market cycles, and preserves capacity to fund strategic investments or compliance without excess leverage.
Read all positive factors
Cronos Australia Ltd. (VIT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$17.23M
Dividend Yield7.69%
Average Volume (3M)228.84K
Price to Earnings (P/E)21.7
Beta (1Y)1.50
Revenue Growth2.11%
EPS Growth-64.71%
CountryAU
Employees72
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)<0.01
Shares Outstanding662,741,800
10 Day Avg. Volume238,134
30 Day Avg. Volume228,844
Financial Highlights & Ratios
PEG Ratio-1.00
Price to Book (P/B)0.78
Price to Sales (P/S)0.30
P/FCF Ratio14.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cronos Australia Ltd. Business Overview & Revenue Model
Company Description
Established in 2018 and based in South Yarra, Australia, Vitura Health Limited focuses on the supply and marketing of medicinal cannabis goods throughout Australia and the Asian market. The company manages a portfolio of key brands, such as CanVie...
How the Company Makes Money
null...
Cronos Australia Ltd. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
72
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 129.24M | 124.04M | 123.87M | 117.34M | 66.99M | 21.71M |
| Gross Profit | 19.87M | 33.75M | 34.22M | 25.96M | 25.43M | 3.19M |
| EBITDA | 4.15M | 5.64M | 7.08M | 21.08M | 10.87M | 2.12M |
| Net Income | 784.13K | 3.32M | 3.51M | 13.81M | 6.05M | -4.05M |
Balance Sheet | ||||||
| Total Assets | 76.85M | 75.49M | 71.28M | 46.90M | 42.87M | 12.69M |
| Cash, Cash Equivalents and Short-Term Investments | 6.10M | 7.58M | 11.35M | 18.85M | 16.08M | 9.47M |
| Total Debt | 17.34M | 11.97M | 11.02M | 1.71M | 5.06M | 718.02K |
| Total Liabilities | 31.49M | 27.89M | 32.84M | 11.99M | 16.79M | 3.47M |
| Stockholders Equity | 46.11M | 48.20M | 38.78M | 34.98M | 26.10M | 9.30M |
Cash Flow | ||||||
| Free Cash Flow | 1.38M | 2.58M | 6.21M | 8.78M | 13.13M | 1.01M |
| Operating Cash Flow | 1.48M | 2.67M | 7.00M | 9.71M | 13.50M | 1.07M |
| Investing Cash Flow | -4.95M | -13.87M | -13.20M | -837.72K | 2.00M | -160.69K |
| Financing Cash Flow | 2.18M | 7.43M | -1.30M | -6.10M | -1.50M | -262.03K |
Cronos Australia Ltd. Technical Analysis
Negative
0.03
Price Trends
0.03
Negative
0.03
Negative
0.05
Negative
Market Momentum
>-0.01
Positive
14.56
Positive
-42.06
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VIT, the sentiment is Negative. The current price of 0.03 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 14.56 is Positive, neither overbought nor oversold. The STOCH value of -42.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:VIT.
Cronos Australia Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | AU$132.67M | 13.12 | 19.15% | 4.33% | 17.31% | 17.99% | |
58 Neutral | AU$17.23M | 21.67 | 1.66% | 6.67% | 2.11% | -64.71% | |
55 Neutral | AU$61.27M | -16.09 | -1.67% | ― | 15.21% | -141.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$2.90M | -0.33 | -76.30% | ― | 3.64% | -23.56% | |
43 Neutral | AU$4.15M | 0.22 | 93.89% | ― | -29.95% | ― | |
42 Neutral | AU$20.02M | -5.07 | 4388.00% | ― | -53.90% | 57.52% |
* Healthcare Sector Average
AU:VIT
Cronos Australia Ltd.
0.03
-0.05
-64.79%
AU:EXL
Elixinol Wellness
0.02
>-0.01
-11.76%
AU:CAN
Cann Group
0.01
>-0.01
-28.57%
AU:VLS
Vita Life Sciences Limited
2.50
0.41
19.62%
AU:LGP
Little Green Pharma Ltd.
0.08
-0.04
-36.67%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-29.17%
Cronos Australia Ltd. Corporate Events
Vitura Health Tightens Capital Structure as Rights and Options Lapse
Jul 27, 2026
Vitura Health Limited has notified the market of changes to its issued capital, with more than 4 million performance rights and options ceasing on 27 July 2026. The lapse of conditional performance rights and expiry of unexercised options reduces ...
Vitura reshapes leadership team to cut costs and sharpen patient focus
Jul 22, 2026
Vitura Health Limited has announced two senior appointments as part of a broader leadership and structural overhaul designed to boost efficiency and sharpen its patient-focused strategy. James Frayne will join as Chief Financial Officer, bringing ...
Vitura Health Updates Corporate Address as Digital Health Network Expands
Jul 8, 2026
Vitura Health Limited has updated its registered office and principal place of business to new premises in South Yarra, Victoria, while keeping its website and contact details unchanged. The move consolidates the company’s corporate presence...
Vitura installs interim CFO as CEO launches finance leadership overhaul
Jun 4, 2026
Vitura Health has appointed former long-serving finance chief Tom Howitt as interim CFO following the resignation of Andrew Cook, who departed during his probationary period to pursue an external senior role aligned with his long-term career goals...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.